| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3dfa2c16bb240755518c00728eaeaa1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-864
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2016-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eb3fef2e6576ffa14d785079c7542df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa085afd34634495bd5fdaa8d0f1de5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d685387144484fb4ad7955cb66d0f5a |
| publicationDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017082701-A1 |
| titleOfInvention |
Pharmaceutical composition for treatment of cardiac fibrosis |
| abstract |
The present invention relates to a pharmaceutical composition for the treatment of cardiac fibrosis or heart diseases accompanied by cardiac fibrosis. According to the present invention, the composition of the present invention has an effect of dissolving a fibrosis matrix and performing restoration to normal tissues by selectively destroying myofibroblasts in cardiac fibrosis which is diagnosed after a disease occurs, and therefore can be usefully used as a composition for the treatment of cardiac fibrosis, systolic heart failure and diastolic heart failure for which a therapeutic agent has not been developed due to being considered as an irreversible disease progression up to date. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7240749-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7232441-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111542334-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3690054-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113143919-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113143919-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020101461-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020536519-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111465697-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111465697-B |
| priorityDate |
2015-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |